Targeted therapy in lymphoma

Patrick Bruce Johnston, Ruirong Yuan, Franco Cavalli, Thomas Elmer Witzig

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Discovery of new treatments for lymphoma that prolong survival and are less toxic than currently available agents represents an urgent unmet need. We now have a better understanding of the molecular pathogenesis of lymphoma, such as aberrant signal transduction pathways, which have led to the discovery and development of targeted therapeutics. The ubiquitin-proteasome and the Akt/mammalian target of rapamycin (mTOR) pathways are examples of pathological mechanisms that are being targeted in drug development efforts. Bortezomib (a small molecule protease inhibitor) and the mTOR inhibitors temsirolimus, everolimus, and ridaforolimus are some of the targeted therapies currently being studied in the treatment of aggressive, relapsed/refractory lymphoma. This review will discuss the rationale for and summarize the reported findings of initial and ongoing investigations of mTOR inhibitors and other small molecule targeted therapies in the treatment of lymphoma.

Original languageEnglish (US)
Article number45
JournalJournal of Hematology and Oncology
Volume3
DOIs
StatePublished - 2010

Fingerprint

Lymphoma
Sirolimus
Poisons
Proteasome Endopeptidase Complex
Therapeutics
Ubiquitin
Protease Inhibitors
Signal Transduction
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Molecular Biology

Cite this

Targeted therapy in lymphoma. / Johnston, Patrick Bruce; Yuan, Ruirong; Cavalli, Franco; Witzig, Thomas Elmer.

In: Journal of Hematology and Oncology, Vol. 3, 45, 2010.

Research output: Contribution to journalArticle

@article{16c185bfaae4409c802140d794795ca4,
title = "Targeted therapy in lymphoma",
abstract = "Discovery of new treatments for lymphoma that prolong survival and are less toxic than currently available agents represents an urgent unmet need. We now have a better understanding of the molecular pathogenesis of lymphoma, such as aberrant signal transduction pathways, which have led to the discovery and development of targeted therapeutics. The ubiquitin-proteasome and the Akt/mammalian target of rapamycin (mTOR) pathways are examples of pathological mechanisms that are being targeted in drug development efforts. Bortezomib (a small molecule protease inhibitor) and the mTOR inhibitors temsirolimus, everolimus, and ridaforolimus are some of the targeted therapies currently being studied in the treatment of aggressive, relapsed/refractory lymphoma. This review will discuss the rationale for and summarize the reported findings of initial and ongoing investigations of mTOR inhibitors and other small molecule targeted therapies in the treatment of lymphoma.",
author = "Johnston, {Patrick Bruce} and Ruirong Yuan and Franco Cavalli and Witzig, {Thomas Elmer}",
year = "2010",
doi = "10.1186/1756-8722-3-45",
language = "English (US)",
volume = "3",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Targeted therapy in lymphoma

AU - Johnston, Patrick Bruce

AU - Yuan, Ruirong

AU - Cavalli, Franco

AU - Witzig, Thomas Elmer

PY - 2010

Y1 - 2010

N2 - Discovery of new treatments for lymphoma that prolong survival and are less toxic than currently available agents represents an urgent unmet need. We now have a better understanding of the molecular pathogenesis of lymphoma, such as aberrant signal transduction pathways, which have led to the discovery and development of targeted therapeutics. The ubiquitin-proteasome and the Akt/mammalian target of rapamycin (mTOR) pathways are examples of pathological mechanisms that are being targeted in drug development efforts. Bortezomib (a small molecule protease inhibitor) and the mTOR inhibitors temsirolimus, everolimus, and ridaforolimus are some of the targeted therapies currently being studied in the treatment of aggressive, relapsed/refractory lymphoma. This review will discuss the rationale for and summarize the reported findings of initial and ongoing investigations of mTOR inhibitors and other small molecule targeted therapies in the treatment of lymphoma.

AB - Discovery of new treatments for lymphoma that prolong survival and are less toxic than currently available agents represents an urgent unmet need. We now have a better understanding of the molecular pathogenesis of lymphoma, such as aberrant signal transduction pathways, which have led to the discovery and development of targeted therapeutics. The ubiquitin-proteasome and the Akt/mammalian target of rapamycin (mTOR) pathways are examples of pathological mechanisms that are being targeted in drug development efforts. Bortezomib (a small molecule protease inhibitor) and the mTOR inhibitors temsirolimus, everolimus, and ridaforolimus are some of the targeted therapies currently being studied in the treatment of aggressive, relapsed/refractory lymphoma. This review will discuss the rationale for and summarize the reported findings of initial and ongoing investigations of mTOR inhibitors and other small molecule targeted therapies in the treatment of lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=78549233720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78549233720&partnerID=8YFLogxK

U2 - 10.1186/1756-8722-3-45

DO - 10.1186/1756-8722-3-45

M3 - Article

C2 - 21092307

AN - SCOPUS:78549233720

VL - 3

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

M1 - 45

ER -